One Stop Solution For In-Depth Market Research Reports


Home    >    HEALTHCARE AND PHARMACEUTICALS   >   Acute Agitation and Aggression Treatment Market

[ 英語タイトル ] Acute Agitation and Aggression Treatment Market - Growth, Trends, and Forecasts (2020 - 2025)

Product Code : MDHC0084272
Survey : Mordor Intelligence
Publish On : November, 2020
Number of Pages : 111
Category : Healthcare and Pharmaceuticals
Study Area : Global
Report format : PDF
Sales price option (consumption tax not included)
Single User USD4250 / Question Form
5 User USD4750 / Question Form
Enterprise User USD7500 / Question Form
 - Eli Lilly and Company
- Pfizer, Inc.
- Otsuka Holdings
- GlaxoSmithKline
- H. Lundbeck A/S
- Johnson & Johnson
- Bristol-Myers Squibb

[Report Description]

Global Acute Agitation and Aggression Treatment market is expected to witness a CAGR of 4.9% during the forecast period. Certain factors that are driving the market growth include rise in burden of mental illness and increase in agitation in patients, increase in focus on creating awareness about agitation and aggression, and ongoing research on the development of novel treatment for agitation.

According to the statistics provided by the Mental Health Foundation in 2018, mental health problems are one of the primary causes of rising medical concerns. In addition, according to the United States Census Bureau’s Statistics, as of 2017, the total number of people aged 65 and older exceeds 50 million, and between 2020-2030, the number of elderly population is projected to increase by almost 18 million. Although much smaller in the total size, the number of people aged between 85 years and older is expected to be more than tripled, from an estimated 6 million in 2017, to nearly 20 million by 2060. Furthermore, mental and behavioral health problems are considered to be the primary cause of disability in the elderly population.

Key Market Trends

Anti-psychotics is Expected to Hold Significant Market Share in the Drug Class Segment

The typical antipsychotics cause sedation, given a high enough dose. Haloperidol, a high potency butyrophenone, has been frequently used as an intramuscular as-needed medication for agitation and aggressive behavior in an emergency department setting for a wide variety of patients. Droperidol, another antipsychotic in the butyrophenone class, is not approved by the US Food and Drug Administration for psychiatric conditions but has been used for sedating agitated patients in an emergency room setting.

Moreover, robust development pipeline coupled with the activity of the manufacturers in launch and collaborations projected to boost the segment growth. For Instance, in May 2017, Otsuka and Lundbeck announce results of brexpiprazole on symptoms of agitation related to Alzheimer’s-type dementia. Furthermore, the growing burden of risk factors fr agitation and aggression such as neurological disorders projected to bolster the market growth over the forecast period.

North America Dominates the Market and Expected to do Same in the Forecast Period

As per the Mental Health America, more than 44 million American adults have a mental health condition (2017). The most commonly reported agents are benzodiazepines, followed by butyrophenone antipsychotics (e.g., haloperidol, droperidol) as reported by directors of emergency medicine residencies and pediatric emergency medicine fellowships in the United States. Moreover, within the United States, approximately 5.7 million people are living with dementia (Alzheimer’s Association, 2018). All these factors are expected to drive the market growth in the region.

Competitive Landscape

The global acute agitation and aggression treatment market is moderately competitive and consists of a few major players. Companies like Eli Lilly and Company, Pfizer, Inc., Otsuka Holdings, GlaxoSmithKline, H. Lundbeck A/S, Johnson & Johnson, Bristol-Myers Squibb, among others, hold the substantial market share in the Acute Agitation and Aggression Treatment market.

Reasons to Purchase this report:

- The market estimate (ME) sheet in Excel format
- 3 months of analyst support

1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study



4.1 Market Overview
4.2 Market Drivers
4.2.1 Rise in Geriatric Population and Increase in Agitation in Patients
4.2.2 Increase in Focus on Creating Awareness About Agitation and Aggression
4.2.3 Ongoing Research on the Development of Novel Treatment for Agitation
4.3 Market Restraints
4.3.1 Preference for Non-Pharmacological Interventions
4.3.2 Social Stigma Associated With Mental Illness
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry

5.1 By Route of Administration
5.1.1 Oral
5.1.2 Intramuscular
5.1.3 Others
5.2 By Drug Class
5.2.1 Anti-psychotics
5.2.2 Benzodiazepines
5.2.3 Others
5.3 By End Users
5.3.1 Hospitals & Ambulatory Surgical Centers
5.3.2 Psychiatric Care Facilities
5.3.3 Others
5.4 Geography
5.4.1 North America United States Canada Mexico
5.4.2 Europe Germany United Kingdom France Italy Spain Rest of Europe
5.4.3 Asia-Pacific China Japan India Australia South Korea Rest of Asia-Pacific
5.4.4 Middle-East and Africa GCC South Africa Rest of Middle-East and Africa
5.4.5 South America Brazil Argentina Rest of South America

6.1 Company Profiles
6.1.1 Eli Lilly and Company
6.1.2 Pfizer, Inc.
6.1.3 Otsuka Holdings
6.1.4 GlaxoSmithKline
6.1.5 H. Lundbeck A/S
6.1.6 Johnson & Johnson
6.1.7 Bristol-Myers Squibb




Recommended reports